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Abstract
Background: Alternative polyadenylation sites within a gene can lead to alternative transcript
variants. Although bioinformatic analysis has been conducted to detect polyadenylation sites using
nucleic acid sequences (EST/mRNA) in the public databases, one special type, single-block EST is
much less emphasized. This bias leaves a large space to discover novel transcript variants.
Results: In the present study, we identified novel transcript variants in the human genome by
detecting intronic polyadenylation sites. Poly(A/T)-tailed ESTs were obtained from single-block
ESTs and clustered into 10,844 groups standing for 5,670 genes. Most sites were not found in other
alternative splicing databases. To verify that these sites are from expressed transcripts, we analyzed
the supporting EST number of each site, blasted representative ESTs against known mRNA
sequences, traced terminal sequences from cDNA clones, and compared with the data of
Affymetrix tiling array. These analyses confirmed about 84% (9,118/10,844) of the novel alternative
transcripts, especially, 33% (3,575/10,844) of the transcripts from 2,704 genes were taken as high-
reliability. Additionally, RT-PCR confirmed 38% (10/26) of predicted novel transcript variants.
Conclusion: Our results provide evidence for novel transcript variants with intronic poly(A) sites.
The expression of these novel variants was confirmed with computational and experimental tools.
Our data provide a genome-wide resource for identification of novel human transcript variants
with intronic polyadenylation sites, and offer a new view into the mystery of the human
transcriptome.
Background
Eukaryotic mRNA is frequently alternative spliced. Recent
studies of human tissue transcriptomes by high-through-
put sequencing have revealed that about 95% of multi-
exon genes undergo alternative splicing (AS) [1,2]. This
greatly enhances previous estimate of human AS events
[3-5], thus further adds complexity to transcripts and pro-
teins. Alternative cleavage and polyadenylation (APA) is
also an important mechanism to produce diverse mRNA
isoforms. In APA events, a key regulatory step in the for-
mation of the mRNA 3'-end, a nascent mRNA is cleaved at
its cleavage site and the poly(A) tail is added to the mRNA
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[6,7]. Polyadenylation is associated with important cis-
elements, such as the upstream canonical AAUAAA and its
hexamer variants, the downstream U/GU-rich elements,
the auxiliary upstream elements, and the downstream ele-
ments [8-11]. These element combinations determine
how mRNA 3'-ends are processed. In human, over half of
genes have alternative polyadenylation products [9].
These alternative transcripts are often expressed in a tis-
sue-specific pattern, and contribute to some inherited dis-
orders and tumor development [12-16].
In addition to the 3' most exons, polyadenylation sites
(poly(A) sites) can also exist in introns and internal exons.
In human, at least 20% of the genes have intronic polya-
denylation [17]. Alternative tandem or intronic poly(A)
sites can lead to alternative polyadenylation [18]. Bioin-
formatic analysis has revealed different polyadenylation
configuration within gene structure [11,17,19]. The
mRNA produced from an internal polyadenylation site
often encodes truncated proteins or distinct protein iso-
forms. These protein products often show different cellu-
lar localization and/or different functions compared to
the protein produced from the 3'-most poly(A) site [20-
29].
Genome-wide searches for poly(A) sites resulted in the
polyA_DB and PolyA_DB2 (the latest version) databases
[17,30,31]. To date, 54,686 poly(A) sites have been iden-
tified [31]. However, these poly(A) sites are mainly lim-
ited to coding regions, and the frequency of poly(A) sites
in large introns and intergenic regions remains largely
unstudied. In addition, the sequence selection for these
databases was biased towards sequences in the UniGene
database [30,32]. Because intron did not overlap with
known exons or cDNA sequences, most intronic expressed
sequence tag (EST) sequences were excluded. For example,
ESTs located in large introns were removed in Lee's
research [32], because these sequences usually did not
overlap with other sequences for the same gene. No
doubt, this bias leaves a large pool of undiscovered tran-
script variants with intronic polyadenylation sites.
To identify these underrepresented poly(A) sites, we pref-
erentially selected intronic single-block ESTs considering
that ESTs that span multiple exons often have been
included in known UniGene clusters and have been used
for study of alternative splicing. However, single-block
ESTs, which span just one exon on chromosome, were not
well considered [33-37]. We focused on the intronic 3'-
end exon sites associated with poly(A/T)-tailed ESTs
derived from single-block ESTs. An intronic 3'-end exon
site is defined as a terminal exon site located in introns
upstream of the 3'-most exon of the gene. Herein we use
the term "3'-end exon site", but not "3'-end exon" to
describe intronic poly(A/T)-tailed single-block ESTs
because these 3'-end exons are usually incomplete at their
5'-ends and the closest exon junction is ambiguous. As a
result, 10,844 intronic 3'-end exon sites from 5,670
human genes were identified. 45% of all these sites repre-
sent novel transcript variants that are absent from other
alternative splicing related databases. To confirm that
these sites are transcribed, we collected expression data
from non-poly(A/T)-tailed ESTs, full-length cDNAs, end-
pair sequencing of cDNA clones, and Affymetrix genomic
tiling arrays. These data confirm that about 84% of the
predicted sites represent true transcripts. We also success-
fully verified some predicted transcripts by RT-PCR exper-
iments.
Results
Mapping and clustering intronic poly(A) sites in the human 
genome
To identify novel transcript variants resulting from previ-
ously unidentified intronic poly(A) sites, an annotated
EST alignment file from UCSC Genome Browser http://
genome.ucsc.edu was analyzed (Figure 1). We focused on
single-block ESTs that did not overlap known mRNA
sequences. Initially, 7,948,198 aligned EST entries were
analyzed for poly(A) sites. Among these, 3,614,581 sin-
gle-block EST entries were obtained, containing
3,323,676 non-redundant ESTs. These ESTs could be fur-
ther divided into two type: poly(A/T)-tailed or non-
poly(A/T)-tailed, with the number of 494,529 and
2,829,147, respectively (Table 1). For the poly(A/T)-tailed
ESTs, by blasting these sequences against the RefSeq
mRNA database, known poly(A) sites were identified and
removed, leaving 22,117 sequences for further analysis.
These ESTs were finally clustered into 10,844 groups
(poly(A) clusters) from 5,670 human genes (Table 1 and
Additional file 1, sheet "all_site") according to their posi-
tion overlapping in the chromosome alignment. These
clusters represented 3'-end exon sites. Thus, the involved
gene increased previous reported number that at least
3,344 human genes contained intronic poly(A) sites [17].
The various poly(A/T)-tailed ESTs in the same cluster may
represent heterogeneous cleavage or different polyade-
nylation pattern if they contain different poly(A) sites
[6,11]. Most 3'-end exon sites were flanked by exons con-
taining coding sequences (CDS).
Among the single-block ESTs, 2,829,147 ESTs without
poly(A/T)-tail were grouped in 396,094 clusters. Non-
poly(A) clusters that overlapped with the poly(A/T)-tailed
3'-end exon clusters would support the expression of the
novel transcripts. Of the intronic 3'-end exon sites, 7,676
(71%) from 4,599 genes had at least one supporting non-
poly(A/T)-tailed EST (Additional file 2), and 3,041 (28%)
of the poly(A) clusters contained at least two poly(A/T)-
tailed ESTs (Additional file 1). Totally, 75% (8,189/
10,844) of the identified 3'-end sites were supported by at
least two ESTs. Among the resting 25% supported by only
a single EST, 37% (974/2,655) got further supported byBMC Genomics 2009, 10:518 http://www.biomedcentral.com/1471-2164/10/518
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transcriptional data from Affymetrix genomic tiling array
(see below, Additional file 1 and 2).
There were 351 independent poly(A) clusters that could
overlap with their adjacent clusters via the bridge of non-
poly(A) clusters. Some poly(A) clusters bridged several
non-poly(A) clusters into a single large cluster (data not
shown). These large clusters could just manifest the heter-
ogeneity of the polyadenylation pattern at the 3'-end
exons in the local genomic context [11,38].
A pipeline for identifying novel intronic 3'-end exon sites Figure 1
A pipeline for identifying novel intronic 3'-end exon sites. See Results, and Methods for details.
EST alignment annotation file 
Single-block ESTs 
Poly(A/T)-tailed ESTs    Non-poly(A/T)-tailed  ESTs
Blast against RefSeq mRNA  database  Cluster overlapping ESTs 
Map ESTs to genes, and cluster overlapping ESTs 
Support from non-poly(A/T)-tailed ESTs 
Blast against known mRNA Seqs   
Validation 
tests
Comparison with polyA_DB2, ASAP II, ASTD databases and Muro et al’s data 
Trace sequences based on clone IDs 
RT-PCR validation of interested transcripts 
Comparison with Affymetrix genomic tiling array data 
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3'-end novel transcript variants are expressed
To confirm that these poly(A) sites represent novel alter-
native transcript variants and not genomic DNA contami-
nation, our analysis pipeline had four steps. First, we did
blast searches against all known mRNAs excluding
sequences from RefSeq. Second, for ESTs with clone ID,
we traced their partner sequences of the same clones and
checked for splicing signals within the sequences. Third,
we compared the 3'-end exon sites with the data of
Affymetrix tiling array. Finally, we selected some novel
transcript variants and verified them via RT-PCR experi-
ments.
In our analysis, poly(A/T)-tailed ESTs that had hits in the
RefSeq mRNA database by blast searching were elimi-
nated as known transcripts. However, there are many
mRNAs are not included in the RefSeq database. Most of
the sequences are produced by full-length cDNA sequenc-
ing projects. If our 3'-end ESTs could be aligned well to
such cDNAs, the ESTs were thought to be potential novel
transcripts. Among the 10,844 3'-end exon sites, 2,957
(27%, 2,957/10,844) from 2,257 genes had hits from at
least one mRNA (Table 1 and Additional file 1). This indi-
cates the transcript variants have been cloned by others. As
the full-length cDNA sequencing projects have been con-
ducted with state-of-art quality control as well as manual
verification, it is appropriate that most of these supported
ESTs stand for bona fide mRNAs. The remaining 7,887
sites, involving 3,413 human genes, may represent uni-
dentified 3'-end exon sites for novel transcript variants.
ESTs often have clone IDs, which identify the plasmid
clones of source cDNA fragments. EST sequences are pro-
duced from single-pass sequencing of 5'- and/or 3'-end of
the clones. As we have got the 3'-end single-block ESTs, we
could trace their corresponding 5'-end ESTs with the same
clone IDs. If the 5'-end EST could be split into multiple
blocks, with adjacent GT/AG splicing signal on the human
genome, which could be taken as the exons in mature
mRNAs, it was concluded that the pair of 5'-end and 3'-
end ESTs comprised a bona fide mRNA.
In our data, 3'-end exon sites contained two types of ESTs:
poly(A/T)-tailed and non-poly(A/T)-tailed but over-
lapped with the former. If either type of the ESTs had
multi-block 5'-end ESTs, the 3'-end exon site was thought
to be supported. First, traced sequences were obtained for
the poly(A) ESTs, and 25 novel transcript variants were
obtained (Additional file 3). None of the intronic poly(A/
T)-tailed ESTs for the 25 clones were in PolyA_DB2 data-
base. Second, traced sequences were also obtained for the
non-poly(A) ESTs. From 185,278 non-poly(A/T)-tailed
sequences, 134,658 clone IDs were extracted and 43,595
of these clones had multiple traced sequences. Of these
traces sequences, 8,689 had multiple blocks aligned with
the human genome with at least one block overlapped
with RefSeq mRNAs. These sequences offered supporting
evidence for novel 3'-end exons. Overall, EST clones pro-
vided evidence that 1,155 poly(A) sites from 1,001 genes
represented expressed transcript variants (Table 1 and
Additional file 2).
Table 1: Summary of novel human intronic 3'-end exon sites
Site numbers Genes % all 3'-end exon sites
i. Single-block ESTs
No. of poly(A/T)-tailed ESTs 494,529
No. of non-poly(A/T)-tailed ESTs 2,829,147
No. of final 3'-end exon sites 10,844 5,670 100%
No. supported by non-poly(A/T)-tailed ESTs 7,676 4,599 71%
ii. Validation tests
Blast hit against all known cDNAs 2,957 2,257 27%
Support from EST clone IDs 1,155 1,001 11%
Support from Affymetrix transcripts 5,475 3,627 50%
RT-PCR experiments 10/26
iii. Overlapping with other AS and APA databases
PolyA_DB2 1,410 1,235 13%
ASAP II database 613 554 6%
ASTD database 1,250 1,115 11%
Muro et al's data 4,046 2,895 37%
iv. PAS analysis
PAS positive 7,051 4,292 65%
v. Map domains
At least one domain deletion 7,641 4,142 70%
Transmembrane helix deletion 1,616 945 15%
See Results for details.BMC Genomics 2009, 10:518 http://www.biomedcentral.com/1471-2164/10/518
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Transcriptional fragments from the Affymetrix genomic
tiling array [39], which could support the existence of
transcripts through the specified chromosome region,
were integrated in our analysis. Affymetrix fragments over-
lapped with 5,475 3'-end exon sites (50%) from 3,627
genes (Table 1 and Additional file 2).
Finally, we selected novel isoforms of a couple of genes
which have roles in signal transduction and did nested-
PCR verification. Our interest was to explore the function
of novel protein products encoded by the transcripts. It
was expected that the full coding sequence should be
included in PCR products. The primer strategy was that
the upstream primer (5') was located nearby the transla-
tional start site (ATG) of the RefSeq mRNA, while the
downstream primer (3') should be located in the poly(A/
T)-tailed ESTs. Primer sets were listed in Additional file 4.
The electrophoresis bands of the second PCR products
were shown in Figure 2. Sequences of the PCR products
were made blast search, and were revealed to be novel
(Additional file 4). Sequence analysis was also made with
the BLAT program.
As a result, RT-PCRs confirmed transcription of at least
38% (10 of 26 candidates) of selected intronic poly(A)
sites. Acquired novel sequences and their accession num-
bers in GenBank database were listed in Additional file 4.
In case of MAPK14 (Mitogen-activated protein kinase 14,
also known as p38 alpha.), two novel alternative splicing
variants were obtained, FJ032367 and FJ032368. The lat-
ter had an extra 27 nt resulting from alternative receptor
site in exon 7, just like caspase-9 gamma [40], and a in-
frame pre-stop codon is therefore introduced. The 3'-end
exons that defined novel transcript variants could either
be "hidden exons", not overlapping with any known
exons, or "composite exons", extending known exons
[19]. One "composite exon" and one "hidden exon"
examples were shown in Figure 3A and 3B, respectively.
The 3'-end exon for DLL1 (Delta-like 1) was "composite
exon" (Figure 3A), whereas the pattern for STAMBP
(STAM binding protein) was "hidden exon" (Figure 3B).
The submitted sequences were indicated as "YourSeq" in
each panel (Figure 3A and 3B). A prolonged (Figure 3A)
or an additional block (Figure 3B) relative to the reference
sequences was shown. These blocks represented pro-
longed or novel exons previously unidentified, that is, the
"composite exons" and "hidden exons".
Further analysis of these transcript variants suggested that
these variants complied with GT/AG rules and were not
incompletely processed mRNAs. For the resting 16 candi-
dates that were not successfully cloned, it might be rele-
vant to limited tissue cDNA sources, unsuitable primers,
PCR condition, low expression level of target transcripts,
and non-specific amplification, and so on.
In summary, the majority (84%) of our poly(A) sites were
supported by at least one of validation steps, as well as
non-poly(A/T)-tailed ESTs (Additional file 2). Among
these validation tests, the new isoforms supported by the
RT-PCR, EST clone ID and blast hit against full cDNAs are
more trustable than those only from Affymetrix validation
because the single-block ESTs in the 3'-end exon sites can
be joined to the upstream part of the annotated genes,
whereas sites supported by Affymetrix tiling array may
belong to independent genes hidden in the introns.
Totally, 3,575 (33%, 3,575/10,844) 3'-end exon sites
from 2,704 genes were taken as high-reliability (Addi-
tional file 1, sheet "validation_test"). The resting sites,
whether they were supported by Affymetrix transcrip-
tional fragments or not, were relatively less reliable and
more dependent of experimental validation to exclude
independently expressed transcripts. Among our 10 vali-
dated novel isoforms from RT-PCR experiments, 6 were
still successfully cloned although their 3'-end exons were
not supported by above mentioned EST clone ID and
blast hit against full cDNAs.
The average length of the 3'-end exon sites in our result
was 437 nucleotides, whereas the average length of the 3'-
end exons of all the human RefSeqs was about 820 nucle-
otides. This could be explained by that ESTs just represent
segments of complete transcriptional sequences, and
therefore, a 3'-end exon site just represents partial
sequence of a full 3'-end exon. No doubt, the actual 3'-end
exon could extend toward upstream (5' end), and the pre-
cise nearest exon-exon boundary could be revealed. Theo-
retically, a 3'-end exon site corresponds to one full-length
transcript which needs PCR validation to reveal the com-
plete 3'-end exon. This is the reason that we would like to
use the term "3'-end exon site", but not "3'-end exon" to
describe these incomplete 3'-end exons in our study.
RT-PCR confirms expression of predicted alternative tran- script variants Figure 2
RT-PCR confirms expression of predicted alternative 
transcript variants. The novel transcript variants for 10 
genes are illustrated. These genes are DLL1 (lane 1), MAPK9 
(lane 2), TNFRSF1A (lane 3), and STAMBP (lane 4), MAPK14 
(lane 5), IL16 (lane 6), DGCR2 (lane 7), PDCD6IP (lane 8), 
PIAS1 (lane 9) and IL19 (lane 10). Detail gene information is 
shown in Additional file 4. On the right are size markers (bp), 
which designate 2000 bp, 1500 bp, 750 bp, and 500 bp from 
the top down, respectively.
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Comparison with other alternative splicing related 
databases
To make a comparison with the PolyA_DB2 database, the
accession numbers of poly(A/T)-tailed ESTs as well as the
positions of chromosome alignment of each cluster were
used. As a result, total 1,410 (13%) 3'-end exon sites from
1,235 genes were covered by PolyA_DB2 database (Table
1 and Additional file 1). Among some of these overlap-
ping poly(A) sites, we found more supporting ESTs. For
example, the poly(A) site in PolyA_DB2, Hs.279594.1.27,
included only one poly(A/T)-tailed sequence
(BQ772378), but in our dataset, the corresponding 3'-end
exon site (ExonSiteNo is 3479) was supported by two
poly(A/T)-tailed ESTs (BQ772378 and AW293188), and
seven non-poly(A/T)-tailed ESTs (BF902676, BQ933237,
DB119003, CR744722, AW805980, AI612802, and
AW198031). It suggests from above analysis that our data
can well complement previous studies.
Up to date, many alternative splicing databases have been
developed [33-37,41,42], the main purpose is to collect
all the alternative splicing candidates. It seems that one
important common aspect for these databases is that mul-
tiple-block exons are used for analysis, and precise exon-
intron boundary is required, whereas single-block ESTs
are not well considered. We made a comparison between
our data and two reputed alternative splicing databases,
ASAP II database (released in 2007) [43] and ASTD
(released in 2008) [44], which superseded the ASD (Alter-
native Splicing Database) [41] and ATD (Alternative Tran-
script Diversity) [45] databases. As shown in Table 1 and
Additional file 1, among 10,844 3'-end exon sites, only
Chromosomal alignment results for novel transcripts of DLL1 and STAMBP Figure 3
Chromosomal alignment results for novel transcripts of DLL1 and STAMBP. The alignments for (A) DLL1, (B) 
STAMBP. Blocks show the exons, while the connecting lines depict the introns. Arrows in the connecting lines indicate the 
direction of transcription. The submitted sequences are indicated as "YourSeq" in each panel (A and B). A prolonged (A) or an 
additional block (B) relative to the reference sequences. These blocks represent prolonged or novel exons previously uniden-
tified, that is, the "composite exons" and "hidden exons" [19].
A.
B.BMC Genomics 2009, 10:518 http://www.biomedcentral.com/1471-2164/10/518
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6% (613/10,844) sites from 554 genes were covered by
ASAP II, whereas 11% (1,250/10,844) sites from 1,115
genes were covered by ASTD database (Table 1 and Addi-
tional file 1). This suggests that most of our data are novel.
During our process, Muro et al recently identified 3'-ends
of human and murine genes by automated EST cluster
analysis [46], we compared their data and ours, and found
that about 37% (4,046/10,844) sites from 2,895 genes
were same (Table 1 and Additional file 1). Excluding all
the above crossing 3'-end exon sites and the sites having
blast hit against full cDNAs, a total 45% (4,905/10,844)
from 3,269 genes are novel and unique in our data.
Novel transcript variants are derived from processed 
mature mRNAs
From the sequence analysis shown in Additional file 4, the
canonical splice boundaries (GT/AG in introns) were
implicated. These novel isoforms showed that they were
processed with introns deletion. The gene structures (Fig-
ure 3) of two examples further confirmed that the RT-PCR
products were derived from processed mature mRNAs,
but not unspliced precursor mRNAs. On the other hand,
the clone ID tracing analysis (see above) also revealed that
the novel transcripts were derived from processed mature
mRNAs.
Polyadenylation usually requires a hexamer motif as a pri-
mary 3'-end processing element, which is usually called
the polyadenylation signal (PAS). A 50 nt nucleotide
region preceding the potential cleavage sites of all 17,201
ESTs was searched for the motifs to match at least one of
the thirteen known PAS hexamers (AATAAA, ATTAAA,
TATAAA, AGTAAA, AAGAAA, AATATA, AATACA, CAT-
AAA, GATAAA, AATGAA, TTTAAA, ACTAAA, AATAGA)
[11]. As a result, about 65% (7,051/10,844) of all the 3'-
end exons had at least one of these PAS hexamers (Addi-
tional file 1). Among 2,957 (27%, 2,957/10,844) 3'-end
sites having mRNA hits (see above, Table 1 and Addi-
tional file 1), also about 63% (1,864/2,957) had at least
one of thirteen above mentioned PAS. It suggests from
above analysis that the novel transcript variants be derived
from processed mature mRNAs, but not unspliced precur-
sor mRNAs or degradation products of pre-mRNA.
Novel transcript variants are truncated and missing 
functional domains
Intronic poly(A) sites often lead to truncated isoforms
that lose important functional domain or localization sig-
nals. To evaluate if domains are lost in the novel transcript
variants from intronic poly(A) sites, all protein products
containing the intronic poly (A) sites had been annotated.
Domains were deleted or truncated in transcript variants
from 7,641 poly(A) sites from 4,142 genes (Tables 1 and
Additional file 5). The detailed information of involved
domains in Additional file 5 was shown in Additional file
6. Among all poly(A) sites, 1,616 could lead to deletion of
trans-membrane domain. As an example, the novel iso-
form for TNFRSF1A (Tumor necrosis factor receptor
superfamily, member 1A, also known as TNF-R1 or p55
TNFR), herein designated as TNFRSF1Aβ as it represents
the second isoform of TNFRSF1A, was analyzed.
TNFRSF1A is a death receptor with two known ligands,
tumor necrosis factor and lymphotoxin-α. Through inter-
actions with these ligands, TNFRSF1A initiates cellular sig-
nals and regulates many cellular functions including
inflammation, immune response, proliferation, and
apoptosis [47-50]. The length of PCR product is 1,339 bp
which contains an open reading frame of 657 bp (Figure
4A). TNFRSF1Aβ consists of 218 amino acids (Figure 4A
and 4B), and is generated from an intronic "hidden exon"
between exon 5 and exon 6 (Figure 4C).
TNFRSF1Aβ lacks the trans-membrane helix and the full
cytoplasmic region including the DEATH domain com-
pared to the full-length protein (Figure 4C), while retain-
ing the signal peptide and the conserved binding domain,
that is TNFR (TNF receptor) domain.
Soluble TNFRSF1A, which functions as natural inhibitors
for tumor necrosis factor, was observed and widely inves-
tigated [51-55]. Soluble TNFRSF1A is likely produced
when TACE (tumor necrosis factor-alpha converting
enzyme), a metalloprotease that cleaves transmembrane
proteins, cleaves the TNFRSF1A ecodomain [56-58].
However, TNFRSF1Aβ we found is a natural transcript and
likely encodes a secretory protein product, and may play a
regulatory role preferentially by competitively binding
TNFR ligand (TNF).
As alternate poly(A) sites may be regulated in a tissue- or
disease-specific pattern [59,60], in addition to domain
annotation, expression profiles for novel 3'-end exon sites
were provided (Additional file 7). We compared the EST
distribution in normal and cancerous tissues for each clus-
ter, it revealed that some transcript variants may be can-
cer-specifically expressed. Moreover, an additional
supplemental file (Additional file 8) provided all the can-
didate poly(A) sites of each human genes, integrating
PolyA_DB2, Muro et al's [46] and our results. Totally
112,074 sites of 19,748 genes were included.
Discussion
In this genome-wide analysis, we showed that alternative
polyadenylation in intronic sites can generate lots of
novel transcript variants. We preferentially selected
intronic single-block ESTs for analysis in that these ESTs
were not well considered in previous studies [33-37],
including Lee's research [32]. So, our work is a good com-BMC Genomics 2009, 10:518 http://www.biomedcentral.com/1471-2164/10/518
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Nucleotide and deduced amino acid sequences and the genomic structure of human TNFRSF1A beta Figure 4
Nucleotide and deduced amino acid sequences and the genomic structure of human TNFRSF1A beta. (A) 
Nucleotide and deduced amino acid sequences of TNFRSF1A beta. The PCR amplified sequences (upper case) and 3' pro-
longed untranslated region (lower case) are indicated. The 657 uppercase nucleotides (underlined) are the open reading frame 
of TNFRSF1A beta. The boxed uppercase letters represent the second set primers, while the boxed lowercase is the first set 
downstream primer. The underlined lowercase letters, "attaaa", are the putative polyadenylation signal. The lowercase poly(A) 
tail is also underlined. The nucleotide sequence of TNFRSF1A beta has been submitted to GenBank with the accession number 
EU927389 [GenBank:EU927389]. (B) Amino acid sequence alignment of the novel isoform of TNFRSF1A (TNFRSF1A beta) 
with TNFRSF1A RefSeq [GenBank:NP_001056]. The boxed region indicates the amino acid residues specific for TNFRSF1A 
beta. (C) The genomic structure and organization of functional domains of TNFRSF1A beta. Exons are numbered 1 to 10 at the 
top. Coding exons are represented by blocks connected by horizontal lines representing introns. The 5' and 3' untranslated 
regions (UTRs) are displayed as thinner blocks on the leading and trailing ends of the aligning regions. The 3'-end exon (grey 
block) for of TNFRSF1A beta is located between exon 5 and 6. The signal peptide (S), tumor necrosis factor receptor domain 
(TNFR), and transmembrane helix (TM) and death domain (DEATH) are indicated. Domain regions are numbered.
1    CAAATGGGGGAGTGAGAGGCCATAGCTGTCTGGCATGGGCCTCTCCACCGTGCCTGACCTGCTG
1            MGLSTVPDLL
65    CTGCCACTGGTGCTCCTGGAGCTGTTGGTGGGAATATACCCCTCAGGGGTTATTGGACTGGTC
11    L  P  L  V  L  L  E  L  L  V  G  I  Y  P  S  G  V  I  G  L  V 
128   CCTCACCTAGGGGACAGGGAGAAGAGAGATAGTGTGTGTCCCCAAGGAAAATATATCCACCCT
32    P  H  L  G  D  R  E  K  R  D  S  V  C  P  Q  G  K  Y  I  H  P 
191   CAAAATAATTCGATTTGCTGTACCAAGTGCCACAAAGGAACCTACTTGTACAATGACTGTCCA
53    Q  N  N  S  I  C  C  T  K  C  H  K  G  T  Y  L  Y  N  D  C  P 
254   GGCCCGGGGCAGGATACGGACTGCAGGGAGTGTGAGAGCGGCTCCTTCACCGCTTCAGAAAAC
74    G  P  G  Q  D  T  D  C  R  E  C  E  S  G  S  F  T  A  S  E  N 
317   CACCTCAGACACTGCCTCAGCTGCTCCAAATGCCGAAAGGAAATGGGTCAGGTGGAGATCTCT
95    H  L  R  H  C  L  S  C  S  K  C  R  K  E  M  G  Q  V  E  I  S 
380   TCTTGCACAGTGGACCGGGACACCGTGTGTGGCTGCAGGAAGAACCAGTACCGGCATTATTGG
116   S  C  T  V  D  R  D  T  V  C  G  C  R  K  N  Q  Y  R  H  Y  W 
443   AGTGAAAACCTTTTCCAGTGCTTCAATTGCAGCCTCTGCCTCAATGGGACCGTGCACCTCTCC
137   S  E  N  L  F  Q  C  F  N  C  S  L  C  L  N  G  T  V  H  L  S 
506   TGCCAGGAGAAACAGAACACCGTGTGCACCTGCCATGCAGGTTTCTTTCTAAGAGAAAACGAG
158   C  Q  E  K  Q  N  T  V  C  T  C  H  A  G  F  F  L  R  E  N  E 
569   TGTGTCTCCTGTAGTAAAGTCCTGCTCTGTCGCCCAGGCTGGAATGCAGTGGCGCGATCTCGG
179   C  V  S  C  S  K  V  L  L  C  R  P  G  W  N  A  V  A  R  S  R 
632   CTCACTGCAACCTCTGCCTCCCAGATTCAAGCAATTCTCCTGCTTCAGCCTCCCAAGTAGCTG 
200    L  T   A   T  S  A   S  Q  I   Q  A   I  L   L  L   Q  P   P  K  *   
695   GGATTACAGGCACGTGCCACCATGCCTGGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTC 
758   ACCATCTTGGTCAGGCTGGTCTCAAACTCCTGGTGATCCACCTGCCTCTGCCTCCCAAAGTGC 
821   TGGGATTACAGCCGTGAGCCACTGCACCCAGCCGGCTTCATCTCTTCTTGAAATCACTTTTAT 
884   ACCATTCTATGTGGTTCTCACCATGAGCTTGAGTGGTGGGCTAAAGTGCCTCTCCCTGCTTTC 
947   AGCTTCCTGCTGGGAACTCACTCTCTCAAGTTCCTTCCAGCACCACCCCATAGAGTTCCCATC 
1010  ACTCCACACTGTCCAGTGACAACTCCCAACATGGAAGATCTGCTAGTTCTACAGGGTGCTCTC 
1073  TGGCTGCCCCAGTAACATGTGTTTTTAAATTTTTCACATGCATGTTTGACCCCGACTCCCCGA 
1136  AGTCAGGTACTGTAACTAGCAGTGTCATTTAAGAAAAAGCCCTTTAACCTCTCTTTGCCAAAG 
1199  GATTCTTATCAGCAAAACAGTGATGAAACAACAATCCCATAACAGCTAGCTGGCTACCTTCTC 
1262  AAGCACTTATTAAATGAGGCATAATGATTTTGCTTAATCCTCAATCCTGAGAGGTGGGCGATC 
1325  CCTGTGGTGATGAGGaaaccgaggcttgggggttaatggcttgcctagattcacactgctagc 
  caaggaatgaactggaatttacaccctgaccctgactgcttttcacattttctacacagcctt 
 ttcaagatccctgccaattctaaaattaaatgattctatgattaaaaaaaaaaaaaaaaaa
Novel       MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCT 60 
Refseq      MGLSTVPDLLLPLVLLELLVGIYPSGVIGLVPHLGDREKRDSVCPQGKYIHPQNNSICCT 60 
Novel       KCHKGTYLYNDCPGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVD 120 
Refseq      KCHKGTYLYNDCPGPGQDTDCRECESGSFTASENHLRHCLSCSKCRKEMGQVEISSCTVD 120 
Novel       RDTVCGCRKNQYRHYWSENLFQCFNCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECV 180 
Refseq      RDTVCGCRKNQYRHYWSENLFQCFNCSLCLNGTVHLSCQEKQNTVCTCHAGFFLRENECV 180 
Novel       SCSKVLLCRPGWNAVARSRLTATSASQIQAILLLQPPK---------------------- 218 
Refseq      SCSNCKKSLECTKLCLPQIENVKGTEDSGTTVLLPLVIFFGLCLLSLLFIGLMYRYQRWK 240 
Novel       ------------------------------------------------------------ 
Refseq      SKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPVPSSTFTSSSTYT 300 
Novel       ------------------------------------------------------------ 
Refseq      PGDCPNFAAPRREVAPPYQGADPILATALASDPIPNPLQKWEDSAHKPQSLDTDDPATLY 360 
Novel       ------------------------------------------------------------ 
Refseq      AVVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTPRREATLEL 420 
Novel       ----------------------------------- 
Refseq      LGRVLRDMDLLGCLEDIEEALCGPAALPPAPSLLR 455 
A.
B.
C.BMC Genomics 2009, 10:518 http://www.biomedcentral.com/1471-2164/10/518
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plement for previous study [17,32]. Single-block ESTs
within the intergenic region were not included in our
analysis though some of them represent gene extensions
[61]. Single-block ESTs are often suspected as contamina-
tion of genomic DNA. However, in our analysis, we
showed that about 84% of the EST clusters were sup-
ported by at least one evidence: hit from full-length
cDNA, multiple-block 5'-end ESTs, overlapping with tran-
scribing sites from Affymetrix tiling array, or having mul-
tiple supporting ESTs. So by carefully screening, the
single-block ESTs could be used as valuable resources for
discovering novel transcripts. Besides focusing on single-
block ESTs, the pipeline in our analysis was designed to
improve poly(A) site detection, all these contribute to the
discovery of novel intronic 3'-end exons. During our anal-
ysis, we found that more than 90% of the EST entries in
our results were created before the polyA_DB2 was
released. It implied that most of the novel transcript vari-
ants were derived by the improvement of our detection
methods and the consideration of single-block ESTs, but
not merely by the growth of the transcript databases.
Although different methods have been used for poly(A)
site prediction [10,62], current methods achieve only
moderate sensitivity and specificity. For example, about
47% of known poly(A) sequences in the polyA_DB data-
base were not predicted the Support Vector Machine
(polya_svm) [10]. Among our predicted 3'-end exon sites,
less than thirty can be predicted by polya_svm (threshold
= 0.5 when the genomic region containing the poly(A)
cluster region ± 300 nucleotides was used for predictions).
However, 68% of the 17,201 ESTs, which correspond to
about 63% of the 10,844 3'-end exons (Additional file 1),
have at least one of thirteen known PAS hexamers. This
low detection rate of prediction by polya_svm likely
results from heterogeneity of the intronic poly(A) sites
compared to the conventional 3'-most poly(A) sites.
It is worthy of note, a method different to ours for identi-
fication of 3'-ends of genes was made according to EST fre-
quency histogram along the genome by Muro et al [46].
They show that 22-52% of sequences in commonly used
human and murine "full-length" transcript databases may
not currently end at bona fide polyadenylation sites. Since
the average length of the 3'-end exons of all the current
human RefSeqs is about 820 nucleotides, they will get
longer according to Muro et al 's results. As the compari-
son in the text has shown, Muro et al's method and ours
have respective advantages, and complement each other.
Both methods will contribute to identification of full-
length transcripts.
Novel 3'-end exons we detected could be defined as "hid-
den exons" and "composite exons" described previously
[19]. However, some apparent "hidden exons" could be
actually "composite", because ESTs only represent partial
cDNA sequences and may be extended to overlap with
known exons.
Not all intronic poly(A) sites correspond to actual novel
transcript variants. For example, internal priming, due to
a consecutive string of 'A's in the mRNAs, results in false
positives. For cDNA library construction, oligo-dT is often
used as the primer for first strand cDNA synthesis. This
primer can anneal to the internal priming site, producing
truncated sequences. Internal priming accounts for about
12% for the total 3' ESTs in the database [63]. In previous
study like Tian's [11], the genomic DNA sequence around
the predicted poly(A) site was checked. If there were more
than 6 consecutive 'A's or at least 7 'A's in 10 nt window,
it was suspected to be an internal priming site. However,
when applied the criterion to study the adjacent DNA
sequence of 3'-end of human RefSeq mRNAs, it was found
that 19.4% (6,147/31,642) mRNAs had such A trait at
their 3'-ends. So if using the above criterion, many true
positive sites might be missed. In our analysis, we tried to
reduce internal priming sites by eliminating all ESTs that
could be aligned well with known RefSeq mRNAs (see
Methods).
In order to find novel transcript variants as many as pos-
sible, we did not request an accurate signature of exon
junction and cleavage site. This is different to those previ-
ous reported [17,19,30-32]. The 3'-end exon site provides
the approximate locus of the "composite exons" or the
"hidden exons" for novel isoforms. The supporting ESTs
of a 3'-end exon site further provide proper sites for down-
stream primer designing to amplify the full coding region
of corresponding novel isoforms. We performed RT-PCR
to validate some interested candidates with success rate of
about 38% (10/26, see Results). Sequence analysis
revealed they were derived from processed mature mRNA,
but not unspliced precursor.
In our analysis, although most of the sites are supported
by at least two types of evidences, there are still 1,468 sites
containing only one EST sequence without supporting in
other way. Some of these sites may truly represent novel
transcript variants associated with low expression levels.
For example, the sites DB550185 (ExonSiteNo: 8501),
DB347581 (ExonSiteNo: 8549), DB536313 (ExonSiteNo:
8628), and DB517750 (ExonSiteNo: 9840), and
DB512524 (ExonSiteNo: 10422), they contain only one
EST sequence, but the EST is from a full-length cDNA
clone (Additional file 1 and 3).
One type of RNA polyadenylation controls RNA degrada-
tion in the nucleus [64-66]. The exosome plays a key role
in the surveillance of nuclear mRNA synthesis and matu-
ration. Poly(A) tails guiding RNA to be degraded by the
exosome are usually shorter than those increasing mRNA
stability, and these poly(A) tails are not made strictly ofBMC Genomics 2009, 10:518 http://www.biomedcentral.com/1471-2164/10/518
Page 10 of 15
(page number not for citation purposes)
'A's. These sites were not actively eliminated in our analy-
sis, but they are unlikely to greatly affect the results
because they would not be detected under our stringent
criteria. On the other hand, sequence analysis of the
poly(A/T)-tailed ESTs revealed that PAS did exist in most
of our ESTs. This result combined with other evidences,
suggest our predicted poly(A) sites should represent bona
fide mRNAs, but not unspliced precursor mRNAs, neither
the degradation products.
Another type of RNA quality control is nonsense-medi-
ated mRNA decay (NMD), which selectively degrades
mRNAs that contain a premature translation termination
codon (PTC, also called "nonsense codon") [67,68].
Although NMD mainly acts as quality control to eliminate
faulty transcripts in gene expression, it is also involved in
physiological and pathological functions [68,69]. Usu-
ally, NMD occurs when translation terminates more than
50-55 nucleotides upstream of the exon-exon junction, in
which case components of the termination complex are
thought to interact with the exon-junction complex (EJC)
to elicit NMD [67]. Although 45% of alternatively spliced
mRNAs are predicted to be an NMD target [68], an mRNA
is immune to NMD if translation terminates less than 50-
55 nucleotides upstream of the 3'-most exon-exon junc-
tion or downstream of the junction. This means if a natu-
ral stop codon of an mRNA exists in the 3'-end exon, it is
not subject to NMD. The transcripts predicted in our study
use an alternative 3'-UTRs, assuming that upstream exons
do not change. Because we have not got the full-length
form for each transcripts, we can not estimate the propor-
tion of our results that would be affected by NMD. How-
ever, it has been reported that alternative polyadenylation
may be an NMD-rescue regulatory mechanism in PTC-
containing mRNAs [70]. Our data seem to be consistent
with the view. Actually all the novel transcripts proved by
RT-PCR experiments in our study comprise the natural
stop codon in the last exon. A further analysis revealed
that in nearly all the 3'-end ESTs except some very short
ones, stop codons exist in all three reading frames (data
not shown). So if there were no correct stop codons in the
5'-exons, the stop codon in the 3'-end exons of our result
would be used. This is different to middle exons that may
not contain in-frame stop codons and could not help con-
veniently clone transcripts with complete coding regions.
It should be noted that a large number of non-coding
RNAs (ncRNAs) are expressed from the mammalian
genome [71,72]. These ncRNAs include miRNAs, snoR-
NAs, snRNAs, and piRNAs, and so on, which are involved
in controlling various levels of gene expression in physiol-
ogy and development. Non-coding RNAs can be derived
from antisense or sense transcripts with overlapping or
interlacing exons, or retained introns. To investigate that
whether the internal intronic transcripts in our data actu-
ally represent known ncRNAs, we compared the chromo-
some alignment position between the 3'-end exon sites in
our study and those of human ncRNAs from NONCODE
v2.0 [72]. In 35,2434 human ncRNA entries collected in
NONCODE v2.0, less than one hundred 3'-end exon sites
were overlapped (data not shown). So it seems that most
of our 3'-end exons do not represent known ncRNAs.
Whereas, we found many poly(A) sites were located in the
introns before the coding exons. If they were real, the
potential novel transcripts would be composed of the 5'-
UTR of the original mRNA. Whether the transcripts
encode small ORFs or regulatory small RNAs needs to
study in the future.
Conclusion
In conclusion, our results identify novel 3'-end alternative
splicing isoforms. The expression of these novel variants
was confirmed with computational and experimental
tools. These data provide a genome-wide resource for
identification of novel human transcript variants with
intronic polyadenylation sites, and offer a new view into
the mystery of the human transcriptome.
Methods
Data source
The University of California, Santa Cruz (UCSC) Genome
Browser Database (GBD) http://genome.ucsc.edu pro-
vides a common repository for genomic annotation data,
including comparative genomics, genes and gene predic-
tions, mRNA and EST alignments, and so on [73,74]. The
human EST annotation file (all est), RefSeq mRNAs, all
known mRNA sequences, and RefSeq annotation files
were downloaded from the UCSC bioinformatics web site
(April 2008 version). ESTs were downloaded from the
NCBI dbEST database (ftp://ftp.ncbi.nih.gov/repository/
dbEST/, April 2008 version). The UniGene database was
downloaded from ftp://ftp.ncbi.nlm.nih.gov/repository/
UniGene/. Sequences were aligned by using BLAT pro-
gram http://genome.ucsc.edu/cgi-bin/hgBlat. Perl scripts
were used for data extraction and analysis. The BED files
in NONCODE v2.0 about human non-coding RNAs were
downloaded from http://www.noncode.org/down
load.htm. The annotated chromosomal positions were
used for overlapping analysis with 3'-end exon sites.
Intronic 3'-end exon site identification and EST clustering
To identify novel transcript variants, we focused on
intronic 3'-end exon sites. The outline of data analysis is
shown in Figure 1.
First, single-block ESTs were collected from UCSC
Genome Browser annotation file. The annotation file pro-
vides detailed information including chromosome locali-
zation, transcription direction, blockCount (number of
blocks in the alignment) and blockSizes (comma-sepa-
rated list of sizes of each block). BlockCount loosely
reflects the alignment exon number. BlockCountBMC Genomics 2009, 10:518 http://www.biomedcentral.com/1471-2164/10/518
Page 11 of 15
(page number not for citation purposes)
increases as EST quality decreases. Many ESTs were anno-
tated for multiple blockcounts but are really single-block
ESTs. To identify all single-block ESTs, we corrected for
misplaced blocks as follows: if the chromosomal distance
between consecutive blocks was less than 10 nucleotides
or if the chromosomal distance was more than 10 nucle-
otides but the blocksize was less than or equal to 10 nucle-
otides, the blockcount was reduced by one. If the final
blockcount was one, the EST was kept as a single-block
EST.
Second, 3'-end exon sites were identified by a poly(A/T)-
tail. All single-block ESTs were checked for 5'-end 'T's or
3'-end 'A's as poly(A) tails in the reverse and forward ori-
entations, respectively. The EST was firstly requested to
contain at least 10 consecutive 'A's or 'T's in either termi-
nal 100 nucleotides. Then poly(A/T) tail was determined
if one of the following criteria was satisfied: (1) if($seq =
~/^t{0,} [atgcn]{0,5}t{10,}/i || $seq = ~/a{10,} [atgcn]
{0,5}a{0,}$/i || $seq = ~/^t{0,} [atgcn]{0,10}t{12,}/i ||
$seq = ~/a{12,} [atgcn]{0,10}a{0,}$/i || $seq = ~/
^[atgcn]{0,2}t{2,} [atgcn]{0,2}t{8,}/i || $seq = ~/a{8,}
[atgcn]{0,2}a{2,} [atgcn]{0,2}$/i){...}; (2) the EST had
20 or more consecutive 'A's or 'T's in either terminal 100
nucleotides, or the EST had 40 or more consecutive 'A's or
'T's in the entire sequence; (3) the EST had more than 15
'A's or 'T's within a 20 nucleotide window in either termi-
nal 50 nucleotides. The criteria (1) was the most effective
and could identify most of poly(A) tails. More consecutive
'A's or 'T's were needed if interrupted by other nucleotides
because of sequence quality. On the other hand, various
length of vector sequences are contained in some propor-
tion of ESTs, and the poor sequencing quality in the ends
or linker sequences in oligo(T) primers should be con-
cerned, therefore, criteria (2) and (3) were introduced. To
our knowledge, the distance from sequencing primers to
multiple cloning site (MCS) is not too long and 100
nucleotides were used as threshold. These criteria could
provide suitable endurance for sequence quality. The
chromosomal loci for these poly(A/T)-tailed ESTs loca-
tions were regarded as 3'-end exon sites. The remaining
ESTs were considered as non-poly(A/T)-tailed ESTs. Non-
poly(A/T)-tailed ESTs were used as supporting evidence
for novel transcript variant expression if their chromo-
some alignment overlapped with poly(A/T)-tailed ESTs.
Third, the poly(A/T)-tailed EST candidates were used as
queries to blast the RefSeq mRNA database. The E-value
was set at e-10. All ESTs with a hit were removed. The
remaining ESTs were further blasted against all mRNA
database with the same E-value to provide transcriptional
evidence.
Finally, the ESTs were mapped to genes. The transcrip-
tional orientation of a gene was annotated in the down-
loaded file "refSeqAli.txt.gz". The orientation of the EST
sequences relative to their mRNA was determined by the
presence of a 5'poly(T) tail or a 3'poly(A) tail. If both
poly(A) and poly(T) tails existed in the same EST, overlap-
ping poly(A/T)-tailed ESTs were used to determine the
true orientation. Poly(A/T)-tailed ESTs and non-poly(A/
T)-tailed ESTs were clustered according to their chromo-
somal alignments. The start and end positions for each
cluster were recorded as the position of the 3'-end exon
site. The RefSeq gene corresponding to each cluster was
determined. Although many genes have more than one
RefSeq, we always selected the same RefSeq for clusters
from the gene, unless the EST alignment was not within
that RefSeq locus. All the ESTs were analyzed for their tis-
sue source and divided into cancer-originated or normal-
originated.
Tracing sequences via clone IDs
All clone IDs were extracted by EST accession numbers.
For each clone ID, the opposite end sequence was traced.
For each end sequence, the GT/AG splicing boundary
determined the transcriptional orientation. If the traced
sequence had both the same transcription orientation as
the RefSeq mRNA and at least one overlapping alignment
block, the EST clone represented a novel isoform.
Comparison with Affymetrix genomic tiling array data
The transcription fragment file of Affymetrix genomic til-
ing array were downloaded from the UCSC Genome
Browser http://hgdownload.cse.ucsc.edu/goldenPath/
hg18/database/. The chromosomal location of the frag-
ments was compared with the 3'-end exon sites. If the frag-
ments overlapped a 3'-end exon site, the EST represented
a novel transcript variant.
RT-PCR experiments
RT-PCR experiments were made to clone some interested
transcript variants. Nested-PCR was performed. The prim-
ers were shown in Additional file 4. The cDNA template
was the Clontech mixed human multiple tissue cDNA
panel, including ten human tissues (brain, spleen, heart,
skeletal muscle, thymus, liver, pancreas, lung and pla-
centa and kidney). The Touchdown-PCR method had the
following conditions: denaturing for 30 s at 94°C; anneal-
ing for 30 s from 65°C to 60°C, decreasing at 0.5°C each
cycle, for the first 10 cycles and at 60°C for the last 20
cycles; extension for 90 s at 72°C for all cycles, with the
final extension at 72°C for 5 min. Each experiment was
done in a 20 μl PCR reaction volume, containing 2 μl of
template, with a GeneAmp® PCR System 2700 amplifier.
Conditions for the second PCR were the same, except that
3 μl of template derived from the first PCR products were
used. The second PCR products were for electrophoresis
and recovered, then cloned in pGEM-T easy vector
(Promega) or directly sequenced. The sequences were
aligned with the BLAT, ClustalW http://www.ebi.ac.uk/
clustalw/, and BLAST.BMC Genomics 2009, 10:518 http://www.biomedcentral.com/1471-2164/10/518
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Comparison with other alternative splicing related 
databases
The sequences of human alternative splicing variants were
downloaded from the ASAP II http://bio
info.mbi.ucla.edu/ASAP2/ and ASTD http://
www.ebi.ac.uk/astd databases. The poly(A/T)-tailed EST
candidates were used as queries to search these databases
by blast program. The E-value was set at e-10 and mini-
mum match of 60 nt with 80% identity was requested. A
comparison between our and Muro et al's 3'-terminal
sequence data was also made using blast analysis. The
accession numbers of poly(A/T)-tailed ESTs as well as the
positions of chromosome alignment of each cluster were
used for comparison with the PolyA_DB2 database. The
ESTs without hits represent novel 3'-end exons.
To supply a comprehensive list of poly(A) sites, we inte-
grated the PolyA_DB2, Muro et al's [46] and our predic-
tion (Additional file 8). The integration was done
according to the chromosomal location of predicted sites.
Sites that were within 20 nt to each other were taken as
one cluster. For each site, the strand that the site belongs
to was determined by the direction of known mRNA con-
taining the site. Sites those were aligned to random chro-
mosome were eliminated.
Domain mapping
Most intronic poly(A) sites result in changes in CDS
region [17]. To determine the effects of these CDS
changes, we mapped domains in all the potential novel
transcript isoforms with the assumption that the exons
before the novel poly(A) site remain unchanged. Domain
information was extracted from RefSeq. The secretory sig-
nal and trans-membrane helix were analyzed with SignalP
http://www.cbs.dtu.dk/services/SignalP/ and TMHMM
http://www.cbs.dtu.dk/services/TMHMM/, respectively.
Internal priming site evaluation
We downloaded the alignment data of human RefSeq
mRNA from UCSC Genome Browser. The -10 to +10
genomic DNA sequence around the 3'-end was extracted.
If there were more than 6 consecutive 'A's or at least 7 'A's
in 10 nt window, it was taken as a 'A' trait.
In our methods for poly(A) identification as mentioned in
above criteria, especially, the criteria (3), it was likely to
introduce internal priming sites. To try the best to
decrease the false positive results, validation tests (see
above) were performed for the 3'-end exon candidates by
blast analysis against all known mRNA database, tracing
EST clone ID, RT-PCR experiments and comparison with
Affymetrix genomic tiling array data. The 3'-end exon sites
validated by the first three processes produced more relia-
ble results than those validated only by Affymetrix tran-
scriptional fragments or not because of exon overlapping
with the containing genes. Therefore, if the 3'-end exon
candidates were not supported by any of the first three val-
idation tests, all the poly(A/T)-tailed ESTs in these 3'-end
exon candidates were re-analyzed, and an extra criterion
was introduced, i.e. the sequence downstream the poly(A)
sites should not match the corresponding genomic region
as to eliminate internal priming sites as possible as we
can. For this purpose, we compared two types of posi-
tions, the EST alignment 3'-end position in chromosome
and the identified poly(A) site. If their distance was within
20 nt, the corresponding poly(A/T)-tailed EST was kept,
otherwise it was abandoned. Moreover, if all the poly(A/
T)-tailed ESTs were completely matched the genome, or at
most with 5 nt hanging tails without matching, the con-
taining 3'-end exon sites were deleted.
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Additional file 1
Summary information for the 10,844 3'-end exon sites. In sheet 
"all_site" lists the summary information for the 10,844 3'-end exon sites, 
whereas in sheet "validation_test" lists more reliable sites from the valida-
tion tests, blast analysis against all known mRNA database, EST clone ID 
analysis, and RT-PCR experiments. The headings in sheet "all_site" are 
defined as follows: "ExonSiteNo" is the serial number for the 3'-end exons; 
"AccNo" is, in most cases, the first sequence in each poly(A) cluster; 
"Chr" is the aligned chromosome for each site; "StartPos" is the start posi-
tion of the chromosome alignment; "EndPos" is the end position for each 
cluster; "RefSeq" is reference sequence; "Definition" is the UniGene name 
for each RefSeq; "Symbol" is the UniGene symbol. "Locuslink" is the gene-
based ID number; "SiteEST" is the list of poly-(A/T)-tailed ESTs in each 
cluster; "SeqCount" is the number of sequence counts in SiteEST; 
"If_BlastHit" marks whether there is a blast hit in the all known mRNA 
database; and "If_PAS" marks whether there are polyadenylation signals 
in poly(A/T)-tailed ESTs. "If_PolyA_DB2" marks whether this is overlap-
ping sequence in PolyA_DB2. "If_PolyA_DB2" is true if the 3'-end ESTs 
are in PolyA_DB2 database or the 3'-end exon site overlaps a site in 
PolyA_DB2 database. "If_ASAPII", "If_ASTD" and "If Muro et al's 
data" mark whether this is overlapping sequence in ASAP II, ASTD and 
Muro et al's databases, respectively. "If_50aa" marks whether the 3'-end 
exon is behind the position of first 50 amino acid residues encoded by the 
RefSeq. The same headings in sheet "validation_test" have the same 
meaning as in sheet "all_site". "RT-PCR" marks whether the 3'-end exon 
is validated by RT-PCR experiments. "CloneIDSource" marks whether the 
EST clones are derived from poly(A/T)-tailed ESTs or non-poly(A/T)-
tailed ESTs. "ExonSiteNo", "Locuslink", "Symbol", and "Definition" 
have the same meaning in subsequent tables.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-518-S1.xls]BMC Genomics 2009, 10:518 http://www.biomedcentral.com/1471-2164/10/518
Page 13 of 15
(page number not for citation purposes)
Acknowledgements
We thank to Bin Tian (New Jersey Medical School) for kindly providing the 
PolyA_DB2 data set. This work was supported by grants from the National 
Natural Science Foundation of China (grant number 30600549), the 
National High Technology Research and Development Program of China 
(grant number 2006AA02A305), and the Key National S&T Program---
"Major New Drug Development" (grant number 2009ZX09503-004).
References
1. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C,
Kingsmore SF, Schroth GP, Burge CB: Alternative isoform regu-
lation in human tissue transcriptomes.  Nature 2008,
456(7221):470-476.
2. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ: Deep surveying of
alternative splicing complexity in the human transcriptome
by high-throughput sequencing.  Nat Genet 2008,
40(12):1413-1415.
3. Matlin AJ, Clark F, Smith CW: Understanding alternative splic-
ing: towards a cellular code.  Nat Rev Mol Cell Biol 2005,
6(5):386-398.
4. Modrek B, Lee C: A genomic view of alternative splicing.  Nat
Genet 2002, 30(1):13-19.
Additional file 2
Supporting evidence for all 3'-end exon sites. The headings are defined 
as follows: "SupportESTs" are the supporting ESTs for each sites; "Sup-
portCount" is the number of sequence counts in "SupportESTs"; "AffyAr-
raySupport" reveals which cell lines support each site and their expression 
fragment number; "AffyCount" is the total number of detected expression 
fragments in all cell lines; and, "CloneIDSupport" are the corresponding 
clone IDs to the "SupportEST" that are used for tracing end sequences. If 
the traced sequences have multiple blocks that align with the genome and 
these blocks overlapped with known reference sequence for the same genes, 
"CloneIDSupport" is recorded. For each site, the serial position is sepa-
rated into three parts, the clone and both end sequences, respectively. 
"CloneCount" is the total number of clones in "CloneIDSupport". 
"If_BlastHit" marks whether there is a blast hit in the all known mRNA 
database.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-518-S2.xls]
Additional file 3
Novel transcript variants represented by clone ID. Novel transcript var-
iants and their respective EST clones are listed. The headings are defined 
as follows: "Clone ID" is the clone ID for the novel transcript; "AccNo(5'-
end)" and "AccNo(3'-end)" are the accession numbers of the 5'-end and 
3'-end sequences from the same clones, respectively; "SiteType" is the pat-
tern of alternative polyadenylation relative to the reference sequence; 
"PolyA_DB2" identifies if the 3'-end ESTs are in PolyA_DB2 database; 
and "AssSeq" are the assembled sequences for each clone. The upper and 
lowercase indicate the 5'-end and 3'-end sequences, respectively. "AssSeq" 
does not represent the full sequences for the same EST clones. "SiteType", 
"AccNo" and "PolyA_DB2" have the same meaning in subsequent tables.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-518-S3.xls]
Additional file 4
Amplification of novel transcript variants. The headings are defined as 
follows: "AmpSeq" is the amplified cDNA sequence; "PCRlength" is the 
PCR product length; "ProteinSeq" is the putative protein product from the 
"AmpSeq"; "ProLength" is the protein length in "ProteinSeq"; and 
"FirstPrimer(5')", "FirstPrimer(3')", "SecondPrimer(5')" and "Sec-
ondPrimer(3')" are the first and second primer sets, respectively. All the 
primer sequences are given in 5' to 3' orientation.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-518-S4.xls]
Additional file 5
Domain analysis involved in all sites. The headings are defined as fol-
lows: "If_Secretory" is true if SignalP predicts a signal peptide; "TM_List" 
is the list of trans-membrane helices predicted in TMHMM; "TM_Intact" 
are transmembrane helices retained in the novel transcript variants; 
"TM_deletion" are deleted transmembrane helices in the novel transcript 
variant; "ForeDomain" and "PostDomain" indicate whether the deleted 
domains are just before or after the 3'-end site, and "InterruptedDomain" 
indicates that the domain is divided by the site; "If_DomainDeletion" is 
true if at least one domain is deleted in the novel transcript variant.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-518-S5.xls]
Additional file 6
Domain annotation. The headings are defined as follows: "PSS_ID" is a 
unique ID from position-specific scoring matrices; and "CD_accession", 
"CD_name", and "Description" are the accession number, the name of 
conservative domain, and the domain description, respectively.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-518-S6.xls]
Additional file 7
Tissue distribution of poly(A/T)- and non-poly(A/T)-tailed ESTs. The 
headings are defined as follows: "Total_tissue" describes all tissue (includ-
ing cancer) that had EST expression and their corresponding EST counts; 
"Total_tissue_acc" are the accession numbers for tissue types in 
"Total_tissue"; accession numbers for the same tissue are separated by a 
comma; "Cancer_tissue" and "Cancer_tissue_acc" are the same as 
"Total_tissue" and "Total_tissue_acc" with ESTs derived from cancer tis-
sues; "Cancer/total" shows the ratio of cancerous ESTs to all ESTs; 
"Cancer_vs_normal" is the difference when the cancerous EST count is 
subtracted from normal tissue EST count; "AffyArraySupport" from Addi-
tional file 2 is shown as evidence for expression.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-518-S7.xls]
Additional file 8
An integrated poly(A) sites of human genes. The headings are defined 
as follows: The 1-5th columns are the chromosome, site position, strand, 
gene symbol and Entrez Gene ID. The 6-8th columns are the poly(A) site 
number or representative supporting ESTs from PolyA_DB2, Muro et al. 
and our prediction, respectively. The 9th column stands for if there is PAS 
in the upstream of the site. Some sites from PolyA_DB2 have no corre-
sponding mRNA sequences thus can not determine the "strand" informa-
tion.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-518-S8.txt]BMC Genomics 2009, 10:518 http://www.biomedcentral.com/1471-2164/10/518
Page 14 of 15
(page number not for citation purposes)
5. Roberts GC, Smith CW: Alternative splicing: combinatorial
output from the genome.  Curr Opin Chem Biol 2002,
6(3):375-383.
6. Pauws E, van Kampen AH, Graaf SA van de, de Vijlder JJ, Ris-Stalpers
C: Heterogeneity in polyadenylation cleavage sites in mam-
malian mRNA sequences: implications for SAGE analysis.
Nucleic Acids Res 2001, 29(8):1690-1694.
7. Zhao J, Hyman L, Moore C: Formation of mRNA 3' ends in
eukaryotes: mechanism, regulation, and interrelationships
with other steps in mRNA synthesis.  Microbiol Mol Biol Rev 1999,
63(2):405-445.
8. Beaudoing E, Freier S, Wyatt JR, Claverie JM, Gautheret D: Patterns
of variant polyadenylation signal usage in human genes.
Genome Res 2000, 10(7):1001-1010.
9. Hu J, Lutz CS, Wilusz J, Tian B: Bioinformatic identification of
candidate cis-regulatory elements involved in human mRNA
polyadenylation.  Rna 2005, 11(10):1485-1493.
10. Cheng Y, Miura RM, Tian B: Prediction of mRNA polyadenyla-
tion sites by support vector machine.  Bioinformatics 2006,
22(19):2320-2325.
11. Tian B, Hu J, Zhang H, Lutz CS: A large-scale analysis of mRNA
polyadenylation of human and mouse genes.  Nucleic Acids Res
2005, 33(1):201-212.
12. Yeo G, Holste D, Kreiman G, Burge CB: Variation in alternative
splicing across human tissues.  Genome Biol 2004, 5(10):R74.
13. Stamm S, Ben-Ari S, Rafalska I, Tang Y, Zhang Z, Toiber D, Thanaraj
TA, Soreq H: Function of alternative splicing.  Gene 2005,
344:1-20.
14. Venables JP: Aberrant and alternative splicing in cancer.  Cancer
Res 2004, 64(21):7647-7654.
15. Faustino NA, Cooper TA: Pre-mRNA splicing and human dis-
ease.  Genes Dev 2003, 17(4):419-437.
16. Philips AV, Cooper TA: RNA processing and human disease.
Cell Mol Life Sci 2000, 57(2):235-249.
17. Tian B, Pan Z, Lee JY: Widespread mRNA polyadenylation
events in introns indicate dynamic interplay between polya-
denylation and splicing.  Genome Res 2007, 17(2):156-165.
18. Edwalds-Gilbert G, Veraldi KL, Milcarek C: Alternative poly(A)
site selection in complex transcription units: means to an
end?  Nucleic Acids Res 1997, 25(13):2547-2561.
19. Yan J, Marr TG: Computational analysis of 3'-ends of ESTs
shows four classes of alternative polyadenylation in human,
mouse, and rat.  Genome Res 2005, 15(3):369-375.
20. Thomas CP, Andrews JI, Liu KZ: Intronic polyadenylation signal
sequences and alternate splicing generate human soluble
Flt1 variants and regulate the abundance of soluble Flt1 in
the placenta.  Faseb J 2007, 21(14):3885-3895.
21. Peterson ML, Bingham GL, Cowan C: Multiple features contrib-
ute to the use of the immunoglobulin M secretion-specific
poly(A) signal but are not required for developmental regu-
lation.  Mol Cell Biol 2006, 26(18):6762-6771.
22. Boldin MP, Goncharov TM, Goltsev YV, Wallach D: Involvement of
MACH, a novel MORT1/FADD-interacting protease, in Fas/
APO-1- and TNF receptor-induced cell death.  Cell 1996,
85(6):803-815.
23. Iwami KI, Matsuguchi T, Masuda A, Kikuchi T, Musikacharoen T,
Yoshikai Y: Cutting edge: naturally occurring soluble form of
mouse Toll-like receptor 4 inhibits lipopolysaccharide signal-
ing.  J Immunol 2000, 165(12):6682-6686.
24. Tabuchi M, Tanaka N, Nishida-Kitayama J, Ohno H, Kishi F: Alterna-
tive splicing regulates the subcellular localization of divalent
metal transporter 1 isoforms.  Mol Biol Cell 2002,
13(12):4371-4387.
25. Wang H, Wang P, Sun X, Luo Y, Wang X, Ma D, Wu J: Cloning and
characterization of a novel caspase-10 isoform that activates
NF-kappa B activity.  Biochim Biophys Acta 2007,
1770(11):1528-1537.
26. Zervos AS, Faccio L, Gatto JP, Kyriakis JM, Brent R: Mxi2, a
mitogen-activated protein kinase that recognizes and phos-
phorylates Max protein.  P r o c  N a t l  A c a d  S c i  U S A  1995,
92(23):10531-10534.
27. Sanz-Moreno V, Casar B, Crespo P: p38alpha isoform Mxi2 binds
to extracellular signal-regulated kinase 1 and 2 mitogen-acti-
vated protein kinase and regulates its nuclear activity by sus-
taining its phosphorylation levels.  Mol Cell Biol 2003,
23(9):3079-3090.
28. Winchester JS, Rouchka EC, Rowland NS, Rice NA: In Silico char-
acterization of phosphorylase kinase: evidence for an alter-
nate intronic polyadenylation site in PHKG1.  Mol Genet Metab
2007, 92(3):234-242.
29. Pan Z, Zhang H, Hague LK, Lee JY, Lutz CS, Tian B: An intronic
polyadenylation site in human and mouse CstF-77 genes sug-
gests an evolutionarily conserved regulatory mechanism.
Gene 2006, 366(2):325-334.
30. Zhang H, Hu J, Recce M, Tian B: PolyA_DB: a database for mam-
malian mRNA polyadenylation.  Nucleic Acids Res
2005:D116-120.
31. Lee JY, Yeh I, Park JY, Tian B: PolyA_DB 2: mRNA polyadenyla-
tion sites in vertebrate genes.  Nucleic Acids Res 2007:D165-168.
32. Lee JY, Park JY, Tian B: Identification of mRNA polyadenylation
sites in genomes using cDNA sequences, expressed
sequence tags, and Trace.  Methods Mol Biol 2008, 419:23-37.
33. Ji H, Zhou Q, Wen F, Xia H, Lu X, Li Y: AsMamDB: an alternative
splice database of mammals.  Nucleic Acids Res 2001,
29(1):260-263.
34. Hsu FR, Chang HY, Lin YL, Tsai YT, Peng HL, Chen YT, Cheng CY,
Shih MY, Liu CH, Chen CF: AVATAR: a database for genome-
wide alternative splicing event detection using large scale
ESTs and mRNAs.  Bioinformation 2005, 1(1):16-18.
35. Sakharkar MK, Perumal BS, Lim YP, Chern LP, Yu Y, Kangueane P:
Alternatively spliced human genes by exon skipping--a data-
base (ASHESdb).  In Silico Biol 2005, 5(3):221-225.
36. Castrignano T, Rizzi R, Talamo IG, De Meo PD, Anselmo A, Bonizzoni
P, Pesole G: ASPIC: a web resource for alternative splicing
prediction and transcript isoforms characterization.  Nucleic
Acids Res 2006, 34:W440-443.
37. Galperin MY: The Molecular Biology Database Collection:
2008 update.  Nucleic Acids Res 2008, 36:D2-4.
38. Iseli C, Stevenson BJ, de Souza SJ, Samaia HB, Camargo AA, Buetow
KH, Strausberg RL, Simpson AJ, Bucher P, Jongeneel CV: Long-
range heterogeneity at the 3' ends of human mRNAs.
Genome Res 2002, 12(7):1068-1074.
39. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT,
Stadler PF, Hertel J, Hackermuller J, Hofacker IL, et al.: RNA maps
reveal new RNA classes and a possible function for pervasive
transcription.  Science 2007, 316(5830):1484-1488.
40. Wang P, Shi T, Ma D: Cloning of a novel human caspase-9 splice
variant containing only the CARD domain.  Life Sci 2006,
79(10):934-940.
41. Stamm S, Riethoven JJ, Le Texier V, Gopalakrishnan C, Kumanduri V,
Tang Y, Barbosa-Morais NL, Thanaraj TA: ASD: a bioinformatics
resource on alternative splicing.  Nucleic Acids Res 2006:D46-55.
42. Lee C, Atanelov L, Modrek B, Xing Y: ASAP: the Alternative
Splicing Annotation Project.  Nucleic Acids Res 2003,
31(1):101-105.
43. Kim N, Alekseyenko AV, Roy M, Lee C: The ASAP II database:
analysis and comparative genomics of alternative splicing in
15 animal species.  Nucleic Acids Res 2007:D93-98.
44. Koscielny G, Texier VL, Gopalakrishnan C, Kumanduri V, Riethoven
JJ, Nardone F, Stanley E, Fallsehr C, Hofmann O, Kull M, et al.: ASTD:
The Alternative Splicing and Transcript Diversity database.
Genomics 2009, 93(3):213-220.
45. Le Texier V, Riethoven JJ, Kumanduri V, Gopalakrishnan C, Lopez F,
Gautheret D, Thanaraj TA: AltTrans: transcript pattern variants
annotated for both alternative splicing and alternative poly-
adenylation.  BMC Bioinformatics 2006, 7:169.
46. Muro EM, Herrington R, Janmohamed S, Frelin C, Andrade-Navarro
MA, Iscove NN: Identification of gene 3' ends by automated
EST cluster analysis.  P r o c  N a t l  A c a d  S c i  U S A  2008,
105(51):20286-20290.
47. Aggarwal BB: Signalling pathways of the TNF superfamily: a
double-edged sword.  Nat Rev Immunol 2003, 3(9):745-756.
48. Lavrik I, Golks A, Krammer PH: Death receptor signaling.  J Cell
Sci 2005, 118(Pt 2):265-267.
49. Micheau O, Tschopp J: Induction of TNF receptor I-mediated
apoptosis via two sequential signaling complexes.  Cell 2003,
114(2):181-190.
50. Locksley RM, Killeen N, Lenardo MJ: The TNF and TNF receptor
superfamilies: integrating mammalian biology.  Cell 2001,
104(4):487-501.
51. Nophar Y, Kemper O, Brakebusch C, Englemann H, Zwang R, Aderka
D, Holtmann H, Wallach D: Soluble forms of tumor necrosis fac-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Genomics 2009, 10:518 http://www.biomedcentral.com/1471-2164/10/518
Page 15 of 15
(page number not for citation purposes)
tor receptors (TNF-Rs). The cDNA for the type I TNF-R,
cloned using amino acid sequence data of its soluble form,
encodes both the cell surface and a soluble form of the
receptor.  Embo J 1990, 9(10):3269-3278.
52. Porteu F, Nathan C: Shedding of tumor necrosis factor recep-
tors by activated human neutrophils.  J Exp Med 1990,
172(2):599-607.
53. Waetzig GH, Rosenstiel P, Arlt A, Till A, Brautigam K, Schafer H,
Rose-John S, Seegert D, Schreiber S: Soluble tumor necrosis fac-
tor (TNF) receptor-1 induces apoptosis via reverse TNF sig-
naling and autocrine transforming growth factor-beta1.
Faseb J 2005, 19(1):91-93.
54. Serwin AB, Mysliwiec H, Hukalowicz K, Porebski P, Borawska M,
Chodynicka B: Soluble tumor necrosis factor-alpha receptor
type 1 during selenium supplementation in psoriasis
patients.  Nutrition 2003, 19(10):847-850.
55. Taniguchi A, Fukushima M, Nakai Y, Ohgushi M, Kuroe A, Ohya M,
Seino Y: Soluble tumor necrosis factor receptor 1 is strongly
and independently associated with serum homocysteine in
nonobese Japanese type 2 diabetic patients.  Diabetes Care
2006, 29(4):949-950.
56. Ogura H, Tsukumo Y, Sugimoto H, Igarashi M, Nagai K, Kataoka T:
Ectodomain shedding of TNF receptor 1 induced by protein
synthesis inhibitors regulates TNF-alpha-mediated activa-
tion of NF-kappaB and caspase-8.  Exp Cell Res 2008,
314(6):1406-1414.
57. Schlondorff J, Blobel CP: Metalloprotease-disintegrins: modular
proteins capable of promoting cell-cell interactions and trig-
gering signals by protein-ectodomain shedding.  J Cell Sci 1999,
112(Pt 21):3603-3617.
58. Mohan MJ, Seaton T, Mitchell J, Howe A, Blackburn K, Burkhart W,
Moyer M, Patel I, Waitt GM, Becherer JD, et al.: The tumor necro-
sis factor-alpha converting enzyme (TACE): a unique metal-
loproteinase with highly defined substrate selectivity.
Biochemistry 2002, 41(30):9462-9469.
59. Beaudoing E, Gautheret D: Identification of alternate polyade-
nylation sites and analysis of their tissue distribution using
EST data.  Genome Res 2001, 11(9):1520-1526.
60. Zhang H, Lee JY, Tian B: Biased alternative polyadenylation in
human tissues.  Genome Biol 2005, 6(12):R100.
61. Lopez F, Granjeaud S, Ara T, Ghattas B, Gautheret D: The disparate
nature of "intergenic" polyadenylation sites.  Rna 2006,
12(10):1794-1801.
62. Legendre M, Gautheret D: Sequence determinants in human
polyadenylation site selection.  BMC Genomics 2003, 4(1):7.
63. Nam DK, Lee S, Zhou G, Cao X, Wang C, Clark T, Chen J, Rowley
JD, Wang SM: Oligo(dT) primer generates a high frequency of
truncated cDNAs through internal poly(A) priming during
reverse transcription.  Proc Natl Acad Sci USA 2002,
99(9):6152-6156.
64. West S, Gromak N, Norbury CJ, Proudfoot NJ: Adenylation and
exosome-mediated degradation of cotranscriptionally
cleaved pre-messenger RNA in human cells.  Mol Cell 2006,
21(3):437-443.
65. LaCava J, Houseley J, Saveanu C, Petfalski E, Thompson E, Jacquier A,
Tollervey D: RNA degradation by the exosome is promoted
by a nuclear polyadenylation complex.  Cell 2005,
121(5):713-724.
66. Houseley J, LaCava J, Tollervey D: RNA-quality control by the
exosome.  Nat Rev Mol Cell Biol 2006, 7(7):529-539.
67. McGlincy NJ, Smith CW: Alternative splicing resulting in non-
sense-mediated mRNA decay: what is the meaning of non-
sense?  Trends Biochem Sci 2008, 33(8):385-393.
68. Muhlemann O, Eberle AB, Stalder L, Zamudio Orozco R: Recogni-
tion and elimination of nonsense mRNA.  Biochim Biophys Acta
2008, 1779(9):538-549.
69. Stalder L, Muhlemann O: The meaning of nonsense.  Trends Cell
Biol 2008, 18(7):315-321.
70. Gilat R, Shweiki D: A novel function for alternative polyade-
nylation as a rescue pathway from NMD surveillance.  Biochem
Biophys Res Commun 2007, 353(2):487-492.
71. Mattick JS, Makunin IV: Non-coding RNA.  Hum Mol Genet 2006,
15(Spec No 1):R17-29.
72. He S, Liu C, Skogerbo G, Zhao H, Wang J, Liu T, Bai B, Zhao Y, Chen
R: NONCODE v2.0: decoding the non-coding.  Nucleic Acids Res
2008:D170-172.
73. Karolchik D, Baertsch R, Diekhans M, Furey TS, Hinrichs A, Lu YT,
Roskin KM, Schwartz M, Sugnet CW, Thomas DJ, et al.: The UCSC
Genome Browser Database.  Nucleic Acids Res 2003, 31(1):51-54.
74. Karolchik D, Kuhn RM, Baertsch R, Barber GP, Clawson H, Diekhans
M, Giardine B, Harte RA, Hinrichs AS, Hsu F, et al.: The UCSC
Genome Browser Database: 2008 update.  Nucleic Acids Res
2008:D773-779.